Related Experiment Video

Updated: Aug 18, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Tumor necrosis factor and interleukin-6 levels in hypertensive patients with and without left ventricular hypertrophy

David Leibowitz1, David Planer, Fanny Ben-Ivgi

  • 1Coronary Care Unit and Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem. oleibo@hadassah.org.il

Blood Pressure
|April 13, 2005
PubMed

Insights

This study found no consistent link between elevated cytokines like tumor-necrosis factor (TNF) and interleukin-6 (IL-6) and increased left ventricular mass in hypertensive patients. Further research is needed to understand these complex relationships.

Area of Science:

  • Cardiology
  • Immunology
  • Hypertension Research

Background:

  • Hypertension is a major risk factor for cardiovascular disease.
  • Elevated left ventricular mass (LVM) is a marker of cardiac damage in hypertension.
  • Cytokines such as tumor-necrosis factor (TNF) and interleukin-6 (IL-6) may play a role in hypertensive heart disease.

Purpose of the Study:

  • To investigate the association between serum levels of TNF and IL-6 and left ventricular mass in hypertensive patients.
  • To determine if elevated cytokine levels are present in hypertensive individuals with increased left ventricular mass.

Main Methods:

  • Prospective study design.
  • Echocardiography for left ventricular (LV) mass and ejection fraction (EF) measurements.
  • Enzyme-linked immunosorbent assay (ELISA) for serum TNF and IL-6 quantification.

Main Results:

  • 19 out of 35 hypertensive patients (54%) exhibited elevated LV mass.
  • Only 6% of patients with elevated LV mass had detectable TNF levels, and 7% had detectable IL-6 levels.
  • No statistically significant association was found between elevated LV mass and detectable serum TNF or IL-6 levels (p = NS).

Conclusions:

  • Hypertensive patients with elevated left ventricular mass do not consistently show increased serum levels of TNF or IL-6.
  • The role of these specific cytokines in the development of left ventricular hypertrophy in hypertension requires further investigation.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...